Weekly Journal Scan: rethinking factor XIa inhibition after acute coronary syndromes

Clicks: 4
ID: 337948
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #368 of 374 articles by views in european heart journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 374 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
This comment refers to ‘Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event’, published in the New England Journal of Medicine; https://doi.org/10.1056/NEJMoa2608717. FⅪa inhibitors were developed around a very attractive -though not novel- therapeutic proposition: pathological thrombosis might be reduced while largely preserving physiological haemostasis, potentially dissociating efficacy from safety.2,3 LIBREXIA ACS tested this hypothesis in a contemporary ACS setting and prompts consideration of what this strategy of anticoagulation may offer to patients receiving intensive antiplatelet therapy. Moreover, most patients had undergone revascularization during the index hospitalization and were receiving guideline-directed medical therapy. The rationale for adding an oral anticoagulant in this intensively treated population rests on the persistence of high levels of thrombin generation and FⅪ despite effective platelet inhibition. This concept had found clinical support in the results of the ATLAS ACS 2–TIMI 51 trial, in which low-dose rivaroxaban added to antiplatelet therapy reduced cardiovascular death, MI, or stroke, at the cost of increased major and intracranial bleeding.4 FⅪa inhibition with milvexian offered the theoretical possibility of preserving this antithrombotic benefit with less interference with physiological haemostasis.
Reference Key
openalex_W7224925001 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Giovanna Liuzzo, Carlo Patrono
Are you one of these authors? Claim your profile
Journal european heart journal
Year 2026
DOI
10.1093/eurheartj/ehag863
URL
https://doi.org/10.1093/eurheartj/ehag863
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.